Prevalence of cefixime-resistant Neisseria gonorrhoeae in Melbourne, Australia, 2021-2022

Eric P F Chow,Kerrie Stevens,Vesna De Petra,Marcus Y Chen,Catriona S Bradshaw,Norelle L Sherry,Lindley A Barbee,Lenka A Vodstrcil,Ivette Aguirre,Kate L Seib,Kate Maddaford,Deborah A Williamson,Benjamin P Howden,Christopher K Fairley
DOI: https://doi.org/10.1093/infdis/jiae313
2024-06-16
The Journal of Infectious Diseases
Abstract:While ceftriaxone remains the first-line treatment for gonorrhoea, the US CDC recommended cefixime as a second-line treatment in 2021. We tested 1176 Neisseria gonorrhoeae isolates among clients attending the Melbourne Sexual Health Centre in 2021-2022. The prevalence of cefixime resistance was 6.3% (74/1176), azithromycin resistance was 4.9% (58/1176) and ceftriaxone resistance was 0% (0/1176). Cefixime resistance was the highest among women (16.4%, 10/61), followed by men-who-have-sex-with-women (6.4%, 7/109), and men-who-have-sex-with-men (5.8%, 57/982). The prevalence of cefixime-resistant N. gonorrhoeae exceeds the threshold of the 5% resistance level recommended by the World Health Organization; and thus, cefixime treatment would have limited benefits in Australia.
immunology,infectious diseases,microbiology
What problem does this paper attempt to address?